Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 248,204 shares of HCW Biologics Inc. common stock as of September 30, 2026.

Key Highlights

  • Reporting persons: Armistice Capital, LLC (Delaware) and Steven Boyd (United States) filed jointly as the "Reporting Persons."
  • Shares beneficially owned: 248,204 shares of HCW Biologics Inc. common stock, par value $0.0001 per share (CUSIP 40423R303).
  • Percent of class: 9.99% as reported in the filing.
  • Voting and dispositive power: Both reporting persons report 0 sole voting power and 0 sole dispositive power; each reports 248,204 shares of shared voting power and 248,204 shares of shared dispositive power.
  • Direct holder: The shares are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company, which is an investment advisory client of Armistice Capital.
  • Event date: The date of the event requiring this filing is September 30, 2026.

Armistice Capital and Steven Boyd Disclose Ownership Position in HCW Biologics

According to the Schedule 13G filed November 16, 2026, Armistice Capital, LLC serves as the investment manager of Armistice Capital Master Fund Ltd., which is described in the filing as "the direct holder of the Shares." The filing states that "pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund." Steven Boyd, as managing member of Armistice Capital, is similarly deemed to beneficially own the same 248,204 shares.

The filing notes that the Master Fund "specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital." The Master Fund is identified as having "the right to receive dividends from, or the proceeds from the sale of, the reported securities," according to the filing's response to Item 6.

The filing was made in connection with HCW Biologics Inc. (NASDAQ:HCWB), headquartered at 2929 N. Commerce Parkway, Miramar, Florida 33025. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Armistice Capital, LLC and Steven Boyd disclosed a combined beneficial ownership of 248,204 shares of HCW Biologics Inc. common stock, representing 9.99% of the class, with all voting and dispositive power held on a shared basis as of September 30, 2026.